000 02333cam  2200373za 4500
0019.865221
003CaOODSP
00520221107161739
007cr |||||||||||
008181127s2018    oncd    ob   f000 0 eng d
040 |aCaOODSP|beng
043 |an-cn---
0861 |aXC62-1/1-421-20E-PDF
1101 |aCanada. |bParliament. |bHouse of Commons. |bStanding Committee on Health.
24510|aTowards open science |h[electronic resource] : |bpromoting innovation in pharmaceutical research and development and access to affordable medications both in Canada and abroad / |cBill Casey, chair.
24610|aPromoting innovation in pharmaceutical research and development and access to affordable medications both in Canada and abroad
260 |a[Ottawa] : |bHouse of Commons, |c2018.
300 |a1 online resource (viii, 27 pages) : |bgraphs.
4901 |aReport of the Standing Committee on Health ; |v20th report, 42nd Parliament, 1st session
500 |a"November 2018."
500 |aIssued also in HTML format.
500 |aOriginal published on: 2018/11/26; published on: 2018/11/28; published on: 2019/05/09.
500 |aIssued also in French under title: Vers la science ouverte : promouvoir l'innovation en recherche et en développement pharmaceutique, et l'accès à des médicaments abordables au Canada et à l'étranger.
504 |aIncludes bibliographical references.
520 |a"In Canada and around the world, there is rising concern that innovative drugs produced by pharmaceutical companies are no longer affordable and are placing increasing strain on health care budgets. Policy makers have begun to examine ways that public funding for pharmaceutical research and development could address this issue"--Summary, page 1.
69207|2gccst|aPharmaceutical industry
69207|2gccst|aResearch and development
69207|2gccst|aDrugs
7001 |aCasey, Bill, |d1945-
77508|tVers la science ouverte |w(CaOODSP)9.865223
830#0|aReport of the Standing Committee on Health ;|v20th report, 42nd Parliament, 1st session.|w(CaOODSP)9.507061
85640|qPDF|s3.82 MB|uhttps://publications.gc.ca/collections/collection_2018/parl/xc62-1/XC62-1-1-421-20-eng.pdf
8564 |qHTML|sN/A|uhttps://www.ourcommons.ca/DocumentViewer/en/42-1/HESA/report-20